Nuparp 300mg Tablet
Rx RequiredSalt Composition: Rucaparib
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
60 tablets in bottle
About The Product
- Ovarian Cancer
- Prostate Cancer
Nuparp 300mg Tablet contains Rucaparib as an active ingredient. This anticancer medicine belongs to the class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors.
It is prescribed to treat certain types of cancer such as ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and prostate cancer. Also It can be used to treat certain types of cancer in people with specific gene (BRCA) changes.
It works by inhibiting the action of specific enzyme that repairs damaged DNA in the cancer cells, resulting in their death. Close monitoring of blood cell count is necessary while having treatment with this medicine. Take it in the exact dosage prescribed by the doctor.
Uses
- Ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Prostate cancer
Side Effects
The human body reacts differently to Nuparp 300mg Tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.
Some of the common side effects of Palbo 100mg Capsule are mentioned below:
Common
- Rash
- Constipation
- Decrease in appetite
- Diarrhea or indigestion
- Nausea or vomiting
- Changes in the blood count
- Shortness of breath
- Tiredness
Serious
- Severe anemia
- Hypersensitivity reactions
- Sepsis (blood infection)
- Pneumonia
How To Use
- Take Nuparp 300mg Tablet in exact dose as prescribed by the doctor.
- The typical dose of this capsule varies with age and overall health factor of the patient.
- It can be taken with or without food but at a fixed time each day to get better results.
- It should be swallowed as a whole with water without crushing, chewing, or opening the capsule.
- Don't miss a dose or overdose the medicine.
How It Works
Nuparp 300mg Tablet contains Rucaparib as an active ingredient. This anticancer medicine belongs to the class of drugs known as PARP (poly ADP-ribose polymerase) inhibitors.
This tablet is an inhibitor of poly Adenosine diphosphate-ribose polymerase enzymes, including PARP-1, PARP-2, and PARP-3, that play a vital role in DNA repair. It works by inhibiting the action of specific enzyme that repairs damaged DNA in the cancer cells, resulting in their death.
Safety Advice
Avoid the consumption of alcohol while taking Nuparp 300mg Tablet, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.
Do not take Nuparp 300mg Tablet without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breastfeeding women should discuss the potential risks and benefits of the Nuparp 300mg Tablet with their healthcare provider before starting treatment.
Nuparp 300mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Share your medical history with the doctor before starting the Nuparp 300mg Tablet. Do not take it without consulting a doctor if you have any kidney related issue.
Nuparp 300mg Tablet is safe for use in liver disease if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.
FAQs
It is an anti-cancer medication used to treat certain types of cancer such as ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and prostate cancer.
References
- Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., ... & TRITON2 investigators. (2020). Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. Journal of Clinical Oncology, 38(32), 3763-3772 - https://pubmed.ncbi.nlm.nih.gov/32795228/
- Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., ... & Bryce, A. H. (2023). Rucaparib or physician’s choice in metastatic prostate cancer. New England Journal of Medicine, 388(8), 719-732 - https://pubmed.ncbi.nlm.nih.gov/36795891/
- Kerliu, L., Myruski, S., Bhatti, A., Soni, P., Petrosius, P., Pervanas, H. C., & Horton, E. R. (2020). Niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Annals of Pharmacotherapy, 54(10), 1010-1015 - https://pubmed.ncbi.nlm.nih.gov/32172572/
- Swisher, E. M., Kwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I., Oaknin, A., ... & McNeish, I. A. (2021). Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature communications, 12(1), 2487 - https://pubmed.ncbi.nlm.nih.gov/33941784/
- Shirley, M. (2019). Rucaparib: a review in ovarian cancer. Targeted Oncology, 14(2), 237-246. - https://pubmed.ncbi.nlm.nih.gov/30830551/
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
